SMC^® Human SARS-CoV-2 RBD IgG Kit

The assay variation of the SMC Human SARS-CoV-2 RBD IgG Immunoassay kit were studied using twenty-one plasma samples, with roughly half positive and half negative, run in triplicate by 2 different operators on 2 different days. Mean intra-assay variation for all samples was < 15%. Mean inter-assay variation for all samples was < 21%.

This new streamline kit has the following features including:

• For use with the state of the art SMCxPRO^® Ultrasensitive Immunoassay System
• Qualitative assay; for research use only
• Detects SARS-CoV-2 RBD specific IgG antibody within 3 days of PCR positive result
• Requires as little as 2?L of human serum and plasma sample (1:50 recommended dilution)
• Fast assay protocol (one hour capture, 30 minute detection steps)

Assay Buffer SARS-CoV-2 RBD IgG Beads Standard Diluent SARS-CoV-2 RBD IgG Detection Antibody 10X Wash Buffer Buffer D Elution Buffer B

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.